Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma - Wikidata - awgldk - TriplyDB

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

http://www.wikidata.org/entity/Q35108386

about

Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma The significance of genetics for cholangiocarcinoma development Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?Pathogenesis, diagnosis, and management of cholangiocarcinoma New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells Endosomal Na+/H+ exchanger NHE5 influences MET recycling and cell migration.Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.Targeted therapy for biliary tract cancers.New and emerging treatment options for biliary tract cancer.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.New Horizons for Precision Medicine in Biliary Tract Cancers.The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma.Intrahepatic cholangiocarcinoma: current management and emerging therapies.NK4 gene therapy inhibits HGF/Met-induced growth of human cholangiocarcinoma cells.MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas.Expression and clinical relevance of MET and ALK in Ewing sarcomas.The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC).Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients.High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer Adjuvant treatment in biliary tract cancer: to treat or not to treat?Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma.Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma.A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.Emerging drugs for biliary cancer.Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models.Clinicopathological significance of growth factors and their receptors as potential therapeutic targets for biliary tract carcinoma.Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.

P2860

Q21132280-FD9A5970-3457-4081-B1F1-38693C13B049 Q26751224-461BDC44-18B4-4D8C-8630-2284996D474D Q26751655-3857E937-6FEB-4FEE-BECE-1B202D1CA3D3 Q26784091-B5D34510-083E-40E1-9468-990A13FA2624 Q26865749-8F9C7400-E174-4864-9C03-F6027AE8BEF7 Q27002547-BD8A6220-E890-4CA6-9620-97305F82A38F Q28074145-0160E691-F860-4D7A-93C3-65DAFEBF24C2 Q34656747-CC22A745-6016-41D0-8026-0C4A1EA0C39E Q35100996-6C613427-C37B-44AD-B9D2-598BEE937C53 Q35215602-AFC46796-A5EE-4141-99EB-8B908C654BB3 Q36407783-4755420A-9C8C-4624-B3A5-232D23CE64C2 Q36572692-1A2F1E7C-1D09-4042-93A8-B2FBEA41511B Q36860098-0E1219C0-DA9C-4B44-93C0-04D35D1038D0 Q37594373-ED14BD19-FCF3-4381-98D7-13FECF877909 Q37719383-22DB8C53-410E-4836-BC02-7B9CD778DB93 Q37982650-9D46A916-C577-47F3-ACDB-66E75B1CA825 Q38160836-A6538DCF-AAA1-4D22-A07C-713F8846A3FA Q38577917-B420AD5A-1CA0-4BD1-9DEE-2EEDACDFB8E4 Q38619219-7447FB99-64EA-405C-A217-FDB831B5F0C2 Q38806970-83920ADB-4415-4796-A3B5-1E0EDF14B9DB Q38812588-3BDBFCD4-2D51-4D8A-B40E-BB7B738D1FEE Q39025928-384A9323-4832-4948-92F5-BF1C9735D1D0 Q39186928-2D299434-3152-4452-85B8-663A34888B0C Q39211399-063AE1C4-8A35-44CB-AA25-4C18583EBAA8 Q39286355-4DB44E4C-0744-44FA-AE32-95C89C55B10D Q39482081-E90E9808-2304-41E9-8D05-7C1D323B6655 Q41077332-79E45680-616A-456A-8640-1534AFF332B1 Q41231601-B2A45D5C-06F2-4775-9D16-796809A0370A Q41753530-A4E8C17D-3BFF-4FBF-BE23-005F91CAF7D0 Q42414387-44EEEFFD-A5D0-4B06-8838-0ABA04E39954 Q43193059-ED4BE939-C81E-4EE0-8A1F-3562F6ECF0D7 Q43625604-8449B842-002D-4781-9FE0-8A48D87363AD Q44718464-53CD260C-A8F4-4CE5-B484-7153F8666113 Q47861428-2217C2B4-7004-4DC5-83EA-449C9DE94B80 Q48126437-70EDC517-FA5D-4F29-890C-9B4CA8DC2773 Q50350640-822F8E13-8762-4DFD-8F3E-E3E63B8CA695 Q51327505-19AFA724-5CB4-4F53-A0B8-E24621971CA7 Q52576043-F6E115D5-EBD4-44A0-8DC2-B60E91547C81 Q54533998-FE99344D-703B-4B27-B261-863E526B7BBD Q55032209-E36A6BA3-30AD-4E2D-A884-D23272D1349D

P2860

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

http://www.wikidata.org/entity/Q35108386

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

@ast

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

@en

type

label

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

@ast

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

@en

prefLabel

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

@ast

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

@en

P1433

Q35108386-420317B6-F5F7-4575-89F4-7CED99049F9F

P1476

Q35108386-455105F7-BBB4-4F52-BD25-9479C51CE99E

P2093

Q35108386-029060D7-126D-4A4A-B36C-B26F0EF65718

Q35108386-059B8FBA-FA6C-4636-8670-70D2145B7E64

Q35108386-13256BAD-F161-46D1-AEAC-7677C074F484

Q35108386-417E75B6-EFDE-4689-BA93-C7C42B7BB32F

Q35108386-4C186920-CC08-4766-843D-D837A9D59725

Q35108386-78BE7844-C2A9-4C53-BBEF-25DD6A185D32

Q35108386-7E04C522-C1F2-4CCE-A004-207B17E3BCBE

Q35108386-8F97A1E8-77E9-4ADA-9448-19FAA9F38A07

Q35108386-ACA3A097-C220-4C0C-AD8E-7BA0C025BE19

Q35108386-D9B6EF9D-8246-44FF-B04A-0BABDA09BDF5

P2860

Q35108386-1B5D774F-1C63-4E1D-8555-FF3D5971FFCA

Q35108386-20884372-9918-41E9-95A9-09FF1863D681

Q35108386-247161F3-42F9-41E2-B6AD-89F1557FB28C

Q35108386-3ABAEC6B-694F-43B9-A511-1536061F353E

Q35108386-3E7E99DB-5C4E-4DD6-A373-B90E4A23FA3A

Q35108386-496220EF-BFC6-42C1-8B5B-733AB35B1DDF

Q35108386-4A1DA330-CE1D-45E7-A637-9DA70D034597

Q35108386-4B3235AF-110D-48FC-AE2C-49FFF988728E

Q35108386-4EF7AE2C-17FB-4123-B8F8-13EF011F4A75

Q35108386-52D28A43-62C9-4CC4-8282-14340F8960FE

P2888

Q35108386-3BDBBB86-0557-4D47-8864-60BDDAAB3150

P304

Q35108386-1937F22C-F6C2-4ABB-B506-EB45B919F648

P31

Q35108386-8F4FBBF2-B2C4-473D-9962-7F3D88F0BADA

P356

Q35108386-0FED729D-BBCF-4B58-984C-C4D9D3806BD2

P407

Q35108386-42467877-C488-4618-9359-F4ECEA16A867

P433

Q35108386-E8DED305-89DA-4B6A-9A9A-DF36E08878BE

P478

Q35108386-F5030EC6-39E0-4796-85FB-72E747EDF58F

P577

Q35108386-CF942319-F2D9-4175-BB9F-C68B96C4A1CB

P5875

Q35108386-56AF7364-DD99-4BC0-9E26-6E573DB9D325

P698

Q35108386-2F41D009-C5E9-4960-9049-9D143B533080

P921

Q35108386-904FFC42-3A1F-4935-A0A0-A6EDCE7DB773

Q35108386-AE9B09E7-B32E-4D72-805D-E470CB9F000D

P932

Q35108386-9D0BD1AB-5B90-4CCE-8888-8BB440372A5C

P356

P1433

British Journal of Cancer

P1476

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

@en

P2093

A Kokubu

http://www.w3.org/2001/XMLSchema#string

D Yoshikawa

http://www.w3.org/2001/XMLSchema#string

H Furukawa

http://www.w3.org/2001/XMLSchema#string

H Ojima

http://www.w3.org/2001/XMLSchema#string

H Shimizu

http://www.w3.org/2001/XMLSchema#string

M Iwasaki

http://www.w3.org/2001/XMLSchema#string

M Miyamoto

http://www.w3.org/2001/XMLSchema#string

N Hiraoka

http://www.w3.org/2001/XMLSchema#string

T Kono

http://www.w3.org/2001/XMLSchema#string

T Kosuge

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.

Met receptor tyrosine kinase: enhanced signaling through adapter proteins

The Met tyrosine kinase receptor in development and cancer

Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.

Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.

The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma.

Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis.

Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology.

Signaling networks assembled by oncogenic EGFR and c-Met.

P2888

P304

131-138

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.199

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51219680

http://www.w3.org/2001/XMLSchema#string

P698

21673683

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

3137414

http://www.w3.org/2001/XMLSchema#string